Merck Ad Welcomes Vioxx Investigations Ahead Of Senate Hearing
This article was originally published in The Pink Sheet Daily
Executive Summary
An open letter from Merck CEO Ray Gilmartin declares the company's confidence that public scrutiny of its handling of Vioxx will show that it acted responsibly
You may also be interested in...
Senate Vioxx Hearing To Include Merck’s Gilmartin, FDA’s Crawford
A Nov. 18 Senate Finance Committee hearing on the withdrawal of Vioxx will include testimony from Merck CEO Ray Gilmartin
Able Unable To Reform On Its Own? Firm Seeks Consent Decree To Address Manufacturing Issues
“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.
Astellas Ends Aczone Acne Treatment Collaboration Agreement With QLT
QLT now has worldwide marketing rights to the topical acne treatment. Astellas believes labeling proposed by FDA will limit the market profile for Aczone, the company said. Aczone’s user fee deadline is July 7.